-
Health todayObesity, diabetes and GLP-1 refines
Unemployed and unmarried Danes start cardioprotective diabetes drugs less often
Among 81,361 Danes with type 2 diabetes and cardiovascular disease, unemployed men started cardioprotective glucose-lowering drugs at 0.77 times the rate of employed men, and unemployed women 0.81 times.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
Photo review found compounded products in a quarter of surveyed US GLP-1 users
Blinded review of medication photographs classified 25.8% of 322 US adults on weekly semaglutide or tirzepatide as using compounded products, with self-report agreeing for 82.6%.
Peer-reviewed -
Health todayHeart and stroke refines
GLP-1 agonists show no effect on atrial fibrillation in obese HFpEF patients
In 470 matched pairs of obese, non-diabetic patients with heart failure with preserved ejection fraction, GLP-1 receptor agonist treatment was not associated with lower atrial fibrillation incidence (HR 0.86, 95% CI 0.53-1.39), while all-cause mortality was lower (HR 0.42, 95% CI 0.23-0.75).
Peer-reviewed -
Data, models and systemsAI in medicine confirms
Machine learning model predicted deaths best in diabetes with hypertension
Among 2,428 US adults with type 2 diabetes and hypertension in NHANES, a random forest predicted death with an AUC of 0.873, against 0.783 for logistic regression.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
Abdominal obesity and high blood sugar rose in Korean screening from 2014 to 2023
Aggregated national health screening statistics for the Republic of Korea show abdominal obesity rising from 21.0% to 25.5% between 2014 and 2023, with hyperglycaemia and hypertension also higher.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Liraglutide's benefit in US veterans may be larger than the LEADER trial found
Reweighting the LEADER trial onto US veterans with diabetes gave a three-year reduction in major cardiovascular events of 4.6% against 1.6%, a difference within statistical uncertainty.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
Childhood obesity fell four percentage points after school programmes in Spain
A meta-analysis of seven school programmes in 6,716 Spanish schoolchildren found obesity prevalence 4.00 percentage points lower after them, from a baseline of 10.3%.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 new
GLP-1 prescribing without an approved indication rose fifteenfold in US adults
Among 92.4 million US adults with no recorded type 2 diabetes or qualifying obesity, GLP-1 prescribing rose from 0.1% in 2021 to 1.5% in 2025.
Peer-reviewed -
Health todayHeart and stroke refines
GLP-1 drugs lower stroke risk by 17%, little of it explained by blood pressure
A meta-analysis of seven randomised trials in type 2 diabetes found that GLP-1 receptor agonists lowered stroke risk by 17%, with blood pressure lowering explaining about a quarter of it.
Preprint · not peer-reviewed -
Health todayHeart and stroke confirms
Empagliflozin's lower cardiovascular risk is similar across social groups in Medicare
In US Medicare claims, empagliflozin initiators aged 65 and over had a hazard ratio of 0.77 for major cardiovascular events against DPP-4 inhibitors, with no variation by social group.
Peer-reviewed -
Health todayHeart and stroke confirms
GLP-1 users with obesity and raised CRP died less often, with heart attacks unchanged
In 50,009 matched pairs with obesity and raised CRP, death, heart attack and stroke combined were lower with GLP-1 exposure (HR 0.80), almost entirely through fewer deaths (HR 0.61).
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 confirms
SGLT2 inhibitors show no new safety signals in diabetic kidney disease
In two US claims cohorts with type 2 diabetes and stage III to IV kidney disease, SGLT2 inhibitors showed only the known genital infection signal against GLP-1 receptor agonists.
Peer-reviewed